Objectives: To study the association of the American Society of Anesthesiologists (ASA) physical status score with long-term outcome in endometrial cancer.
Introduction
Endometrial cancer is the sixth most common cancer in women worldwide, with highest rates in North America and Eastern and Northern Europe [1] . It is diagnosed predominantly in elderly women, the median age being 62 years at diagnosis [2] . Compared with the general population, women with endometrial cancer have an increased prevalence of comorbid conditions, most importantly obesity and diabetes [3] .
The American Society of Anesthesiologists (ASA) physical status classification system was developed in 1941 to offer clinicians a simple categorization of a patient´s physiological status that can be helpful in predicting operative risk [4] . The time frame around the perioperative period that the ASA physical status classification system encompasses has not been defined. The latest version of the classification system was approved in 2014 [5] . This update included examples of patient characteristics that fit into each ASA physical status score, scaled from I to VI (Supplemental Table 1 ).
Although the ASA physical status classification system is mainly used for prediction of perioperative morbidity and mortality, there is some evidence that it may also predict long-term outcome of cancer patients. In those undergoing radical surgery for urinary bladder cancer or upper tract urothelial carcinoma, ASA physical status score independently predicts overall mortality [6] [7] [8] . Here, we wanted to test a hypothesis that high ASA physical status score is associated with an unfavorable long-term outcome in women with endometrial cancer.
Materials and Methods
Patients who underwent primary surgical treatment for endometrial cancer at the Department of Obstetrics and Gynecology, Helsinki University Hospital, between January 1, 2007 and December 31, 2013 were included in this study. The study was approved by the Institutional Review Board (journal number 135/13/03/03/2013) and the National Supervisory Authority for Welfare and Health (journal number 753/06.01.03.01/2016). Clinicopathologic data were abstracted from institutional medical and pathology records. ASA physical status scores were abstracted from anesthesia records and then revised to comply with the 2014 update of the ASA physical status classification system [5] Differences between groups were compared using the log rank test. Statistical significance was set at P < 0.05. Data were analyzed using the Statistical Package for the Social Sciences version 24 software (IBM Corp., Armonk, New York, USA).
Results
A total of 1166 patients were included in the study ( Simple Cox regression analyses were performed with ASA physical status score I as reference ( Table 2 ). All-cause mortality and non-cancer related mortality were increased in patients whose score was III or IV, and cancer-related mortality was increased in patients whose score was IV. Risk of death was not altered in patients whose score was II.
Covariates for the multivariable survival analyses were selected based on unadjusted analyses of potential risk factors (Table 2 ). In addition to the ASA physical status score, the following covariates showed significant associations with all-cause mortality and were included in the multivariable analysis: age, diabetes, histology, stage, blood hemoglobin concentration and leukocyte count, serum CA125 concentration, and type of adjuvant therapy. In the multivariable analysis, ASA physical status score ≥III, age ≥60, endometrioid grade 3 and nonendometrioid histology, stage II-IV, anemia and elevated serum CA125 increased all-cause mortality (Table 3) . Whole pelvic radiotherapy, chemotherapy
and multimodality treatment decreased all-cause mortality (Table 3) .
Diabetes was not significantly associated with cancer-related mortality in unadjusted analyses. It was excluded from the multivariable analysis of cancer-related mortality, which demonstrated ASA physical status score, age, histology, stage, serum CA125 and type of adjuvant therapy as independent prognosticators (Table 3) . We also re-ran the same model with the cut-off for ASA physical status score set at III instead of IV. ASA physical status score remained an independent predictor of cancer-related mortality (hazard ratio 1.7, 95% confidence interval 1.2-2.4; P = 0.002).
Of the patients with stage I-IIIC2 endometrioid cancer who did not satisfy the low-risk
Milwaukee criteria for lymph node involvement [12] , the lymphadenectomy rate was 84.3% (167/198) in those whose ASA physical status score was I or II, as opposed to 58.0% (156/269) in those whose score was III or IV (P < 0.0001). In patients with stage I-IIIC2 nonendometrioid cancer, the lymphadenectomy rate was 87.9% (29/33) in those whose ASA physical status score I or II, and 75.0% (48/64) in those whose score was higher (P = 0.188). In the subgroup of patients with stage III-IV cancer, 78.5% (62/79) of those with an ASA physical status score of I or II and 55.2% (64/116) of those with a score of III or IV received chemotherapy with a curative intent, defined as a minimum of six cycles of combination chemotherapy (P = 0.001). When patients who were allowed to forgo lymphadenectomy despite not satisfying the low-risk Milwaukee criteria [12] and patients with stage III-IV cancer who received suboptimal chemotherapy were excluded from the multivariable analysis of cancer-related mortality, ASA physical status score remained an independent predictor of poor outcome at a cut-off of III (hazard ratio 1.6, 95% confidence interval 1.1-2.3; P = 0.011) and IV (hazard ratio 2.5, 95% confidence interval 1.4-4.4; P = 0.001).
ASA physical status score, age, diabetes, histology, anemia and CA125 were associated with non-cancer related mortality in unadjusted analyses (Table 2) . ASA physical status score and age were the strongest predictors of non-cancer related mortality in multivariable analysis (Table 3 ).
Of the 217 diabetic patients, 193 (88.9%) had an ASA physical status score of III or IV due to poor control of diabetes or additional comorbidities. Because of the obvious overlap between ASA physical status score and diabetes as covariates in multivariable analyses of all-cause mortality and noncancer related mortality (Table 3) , these analyses were also performed after excluding either ASA physical status score or diabetes. Hazard ratios remained essentially unaltered for the remaining covariates; however, after exclusion of ASA physical status score, diabetes showed a significant effect on both all-cause mortality (hazard ratio 1.4, 95% confidence interval 1.1-1.9; P = 0.018) and non-cancer related mortality (hazard ratio 2.1, 95% confidence interval 1.4-3.1; P = 0.001).
Based on multivariable analyses, ASA physical status score III was chosen as the cut-off for Kaplan-Meier survival analyses. These plots demonstrated a worse overall survival, disease-specific survival and non-cancer related survival for patients whose ASA physical status score was ≥III ( Figure   1A -C). Disease-specific survival was also separately analyzed for patients with stage I and stage II-IV cancer. Compared with patients whose ASA physical status score was ≤II, the survival was worse for patients whose score was ≥III in both subgroups of stages (Figure 2A-B) .
Discussion
Prognostic factors for endometrial cancer have been extensively investigated, with an intention to provide tools for individualized treatment, tailored follow-up, and patient counseling. Stage and features of the primary tumor, such as histologic subtype, grade, depth of myometrial invasion and lymphovascular space invasion, are among the most commonly used prognosticators in clinical practice [13] . Many tissue biomarkers, e.g. L1CAM [14, 15] and estrogen and progesterone receptor status [16] , have been proposed as molecular determinants of patient outcome. Of the blood-based assays, CA125 [17] and HE4 [18] have been suggested to serve as prognostic biomarkers in endometrial cancer. Moreover, abnormalities in the preoperative complete blood count, i.e. anemia, leukocytosis and thrombocytosis, appear to be poor prognostic findings [19] . However, none of the tissue biomarkers or blood-based tests are widely used in gynecologic oncology practices. The Cancer Genome Atlas molecular classification, which divides endometrial cancers into four distinct categories [20] , improves assessment of prognosis compared with conventional risk factors alone and holds promise in reducing overtreatment and undertreatment [21, 22] .
Of the clinical patient characteristics, high age has been found to be associated with poor outcome in endometrial cancer [23, 24] . Specifically, age ≥60 years is an independent predictor of locoregional relapses and disease-related death in stage I endometrial cancer [25] , and was chosen as the cut-off for high age in the current study. Findings on the prognostic significance of obesity and diabetes are less consistent, but prevailing data suggest that they are associated with poor overall survival [3, 26] .
Data presented herein provide a novel prognostic instrument in women with endometrial cancer, as the ASA physical status score was found to be associated with poor long-term outcome. It could be argued that surgical understaging and/or weaker tolerance may have lead to a more frequent use of suboptimal adjuvant therapy in patients with a high ASA physical status score, and, consequently, worse outcome. The evidence for improved survival by adjuvant therapy in endometrial cancer is best for chemotherapy in advanced cases [13] . ASA physical status score remained an independent predictor of cancer-related mortality even after exclusion of patients who were at risk for nodal metastasis as per the Milwaukee criteria [12] but did not undergo lymphadenectomy, and patients with an advanced disease who received suboptimal chemotherapy. ASA physical status score also remained an independent predictor of cancer-related mortality after adjusting for the type of adjuvant therapy. Thus, differences in surgical treatment or adjuvant therapies unlikely explain our findings.
Hazard ratios were quite similar for all significant risk factors in the multivariable analyses of all-cause mortality and non-cancer related mortality. By contrast, compared with ASA physical status score, the hazard ratio was somewhat higher for stage in the multivariable analysis of cancer-related mortality. It should be remembered, however, that the hazard ratio for ASA physical status score did not differ from that for age, a risk factor that was strong enough to be included in two prognostic nomograms for endometrial cancer [27, 28] . The ASA physical status classification system may similarly deserve attention in the prognostication of endometrial cancer. It is noteworthy that this classification system predicted disease-specific survival also in the subgroup of stage I cancers that sometimes tend to leave clinicians with uncertainty regarding the true potential for the disease to recur.
Despite the fact that the ASA physical status classification system was originally developed to predict operative risk [4] , it seems unlikely that a high perioperative mortality can explain the worse outcome of patients with high ASA physical status scores during the whole follow-up time. Six of the seven patients who died within 30 days after surgery had an ASA physical status score of III or IV;
all of them succumbed to stage IVB endometrial cancer, which generally has a very poor prognosis.
We assume that the effect of obesity on the poor outcome of patients with a high ASA physical status score was not considerable because body mass index was not associated with increased all-cause, cancer-related or non-cancer related mortality in univariable analyses. Similarly, based on univariable analysis, diabetes was not associated with cancer-related mortality. The effect of diabetes may be more important on deaths unrelated to endometrial cancer because it increased all-cause mortality and non-cancer related mortality in multivariable analyses after exclusion of ASA physical status score as a covariate.
Our study is strengthened by the large sample size and prospectively maintained database with long follow-up time. One of the end-points was disease-specific survival, which is the ideal outcome of interest after a cancer diagnosis. Detailed clinicopathologic data allowed us to control for the most common confounding factors. Presumably, this mitigated the shortcomings associated with the retrospective design of the study.
Although the external validity of the current findings will need to be verified in other patient samples, it is reassuring that the stage distribution and proportion of nonendometrioid cancers were comparable to findings in the Gynecologic Oncology Group 210 surgical pathological staging study of 5866 patients, with the vast majority being local endometrioid cancers [29] . Further, the proportion of women who had at most a mild systemic disease, based on their ASA physical status score of I or II, was very similar to a population-based analysis of 5408 women who underwent hysterectomy for endometrial cancer across the United States (45% and 43% in our study and in the population-based analysis, respectively) [30] .
The biological mechanisms by which the ASA physical status score might have an impact on endometrial cancer-related mortality remain to be elucidated. However, the current findings can be considered to be consistent with an earlier report in which frailty, i.e. state of low functional reserve seen particularly in old subjects, predicted shortened overall survival and disease-free survival in women with endometrial cancer [31] . It could be speculated that the partly subjective nature of the ASA physical status classification system allows frailty and other difficultly measurable clinical findings to be translated into a worse classification [32] . Clearly, more knowledge is needed to better understand the interaction between physical fitness and cancer survival. 133 (11.4%) *Number of cases 1165 (body mass index missing for one patient) †Type 2 diabetes, n = 215; type 1 diabetes, n = 2 ‡Laparoscopic, n = 829 (including 51 conversions); robotic, n = 72; vaginal, n = 11 Table 2 . Simple Cox regression analyses of all-cause mortality, cancer-related mortality and non-cancer related mortality (n = 1166). ASA, American Society of Anesthesiologists Table 3 . Multivariable Cox regression analyses of all-cause mortality, cancer-related mortality and noncancer related mortality. Patients with available data for all of the selected covariates were included in the models (n = 1044).
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